Australian medical technology company SpeeDx has banked a $22 million equity injection from a US venture capital firm to fund an aggressive push into Europe and the US, with its tool for identifying antibiotic-resistant bacteria.
The investment, from Maryland-based Northpond Ventures, comes after SpeeDx enjoyed success in Australia since being spun out of a now shut-down diagnostics development program inside healthcare giant Johnson & Johnson 11 years ago.
Loading...
Yolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
